<?xml-stylesheet type='text/xsl' href='anzctrTransform.xsl'?>
<ANZCTR_Trial requestNumber="336260">
  <stage>Registered</stage>
  <submitdate>21/11/2010</submitdate>
  <approvaldate>24/11/2010</approvaldate>
  <actrnumber>ACTRN12610001034022</actrnumber>
  <trial_identification>
    <studytitle>Comparison Between the Effectiveness of Fixed Combinations of Prostaglandin Analogues</studytitle>
    <scientifictitle>Comparison Between the Effectiveness of Fixed Combinations of Prostaglandin Analogues Regarding Intraocular Pressure Control</scientifictitle>
    <utrn />
    <trialacronym />
    <secondaryid>None</secondaryid>
  </trial_identification>
  <conditions>
    <healthcondition>Primary open angle glaucoma</healthcondition>
    <healthcondition>Ocular hypertension</healthcondition>
    <conditioncode>
      <conditioncode1>Eye</conditioncode1>
      <conditioncode2>Diseases / disorders of the eye</conditioncode2>
    </conditioncode>
  </conditions>
  <interventions>
    <interventions>Patients will use fixed combinations of prostaglandin analogues plus topical beta blockers available on market during 60 days. Patients will be divided in three groups. Each group will recieve one drug. Intraocular pressure will be compared.
If using drugs prior to study, a washout period of 30 days will be necessary.
Half of patients will receive the drug at mornig (8 a.m.) and half at night (8 p.m.). After 30 days they will change the time to use the drug (crossover regarding the instillation time), without washout between these change.
The drugs are: Xalacom (latanoprost 0.005%/timolol 0.5%) eye drop once day; Ganfort (bimatoprost 0.03%/timolol 0.5%) eye drop once day; and Duotrav (travoprost 0.004%/timolol 0.5%) eye drop once day.</interventions>
    <comparator>The control will be the patient before treatment.
Intraocular pressure behavior will be compared between groups.</comparator>
    <control>Active</control>
    <interventioncode>Treatment: drugs</interventioncode>
  </interventions>
  <outcomes>
    <primaryOutcome>
      <outcome>Intraocular pressure measurement by applanation tonometry (Goldmann Applanation Tonometer)</outcome>
      <timepoint>Baseline
30 days
60 days</timepoint>
    </primaryOutcome>
    <secondaryOutcome>
      <outcome>Adverse effects at 30 days self reported such as hyperemia, itching, blurring.</outcome>
      <timepoint>30 days</timepoint>
    </secondaryOutcome>
  </outcomes>
  <eligibility>
    <inclusivecriteria>Intra ocular pressure over 21 MMHG</inclusivecriteria>
    <inclusiveminage>18</inclusiveminage>
    <inclusiveminagetype>Years</inclusiveminagetype>
    <inclusivemaxage>90</inclusivemaxage>
    <inclusivemaxagetype>Years</inclusivemaxagetype>
    <inclusivegender>Both males and females</inclusivegender>
    <healthyvolunteer>No</healthyvolunteer>
    <exclusivecriteria>Pregnancy</exclusivecriteria>
  </eligibility>
  <trial_design>
    <studytype>Interventional</studytype>
    <purpose>Treatment</purpose>
    <allocation>Randomised controlled trial</allocation>
    <concealment>Intraocular pressure higher than 21 mmhg
Need to use drops to reduce intraocular pressure
One investigator will evaluate the patients, enroll them and proceed the allocation after use a randomised number generate by a computer program. He will give the drug to the patient and will not participate from statistical analysis.</concealment>
    <sequence>Program at randomizer.org site</sequence>
    <masking>Blinded (masking used)</masking>
    <assignment>Parallel</assignment>
    <designfeatures />
    <endpoint>Safety/efficacy</endpoint>
    <statisticalmethods />
    <masking1 />
    <masking2 />
    <masking3 />
    <masking4 />
    <patientregistry />
    <followup />
    <followuptype />
    <purposeobs />
    <duration />
    <selection />
    <timing />
  </trial_design>
  <recruitment>
    <phase>Not Applicable</phase>
    <anticipatedstartdate>1/10/2010</anticipatedstartdate>
    <actualstartdate />
    <anticipatedenddate />
    <actualenddate />
    <samplesize>60</samplesize>
    <actualsamplesize />
    <recruitmentstatus>Recruiting</recruitmentstatus>
    <recruitmentcountry>,Outside</recruitmentcountry>
    <recruitmentstate />
    <countryoutsideaustralia>
      <country>Brazil</country>
      <state>Mato Grosso do Sul
CEP: 79000-000</state>
    </countryoutsideaustralia>
    <countryoutsideaustralia>
      <country>Brazil</country>
      <state>MS</state>
    </countryoutsideaustralia>
  </recruitment>
  <sponsorship>
    <primarysponsortype>Individual</primarysponsortype>
    <primarysponsorname>Enyr Saran Arcieri</primarysponsorname>
    <primarysponsoraddress>Rua Francisco Sales, 186
Uberlandia - MG - BRAZIL
CEP 38411-092</primarysponsoraddress>
    <primarysponsorcountry>Brazil</primarysponsorcountry>
    <fundingsource>
      <fundingtype>Self funded/Unfunded</fundingtype>
      <fundingname />
      <fundingaddress />
      <fundingcountry>Brazil</fundingcountry>
    </fundingsource>
    <secondarysponsor>
      <sponsortype>None</sponsortype>
      <sponsorname />
      <sponsoraddress />
      <sponsorcountry />
    </secondarysponsor>
  </sponsorship>
  <ethicsAndSummary>
    <summary>Patients with primary open angle glaucoma or ocular hypertensio will be treated with fixed combinations of prostaglandin analogues plus beta blocker.
They will be follow for 60 days.
Intraocular pressure will be compared. Comparisons beteween groups and with baseline.</summary>
    <trialwebsite>None</trialwebsite>
    <publication>Not yet</publication>
    <ethicsreview>Not yet submitted</ethicsreview>
    <publicnotes />
    <ethicscommitee>
      <ethicname>Uniderp Ethics Committee</ethicname>
      <ethicaddress>City: Campo Grande
State: Mato Grosso do Sul (MS)
CEP: 79000-000</ethicaddress>
      <ethicapprovaldate />
      <hrec />
      <ethicsubmitdate>1/08/2010</ethicsubmitdate>
      <ethiccountry>Brazil</ethiccountry>
    </ethicscommitee>
  </ethicsAndSummary>
  <attachment />
  <contacts>
    <contact>
      <title />
      <name>Enyr Saran Arcieri</name>
      <address>Rua Francisco Sales, 186
Uberlandia - Minas Gerais - Brazil
CEP 38411-092</address>
      <phone>553432364540</phone>
      <fax />
      <email>rsaran@triang.com.br</email>
      <country>Brazil</country>
      <type>Scientific Queries</type>
    </contact>
    <contact>
      <title />
      <name>Enyr Saran Arcieri</name>
      <address>Rua Francisco Sales, 186
Uberlandia - Minas Gerais - Brazil
CEP 38411-092</address>
      <phone>553432364540</phone>
      <fax />
      <email>rsaran@triang.com.br</email>
      <country>Brazil</country>
      <type>Public Queries</type>
    </contact>
    <contact>
      <title />
      <name>Enyr Saran Arcieri</name>
      <address>Rua Francisco Sales, 186
Uberlandia - Minas Gerais - Brazil
CEP 38411-092</address>
      <phone>553432364540</phone>
      <fax />
      <email>rsaran@triang.com.br</email>
      <country />
      <type>Updating Information</type>
    </contact>
    <contact>
      <title />
      <name />
      <address />
      <phone />
      <fax />
      <email />
      <country />
      <type>Principal Investigator</type>
    </contact>
  </contacts>
</ANZCTR_Trial>